RecruitingNot applicableNCT07001280
A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)
Studying Hereditary angioedema
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CSL Behring
- Principal Investigator
- Global Program DirectorCSL Behring
- Intervention
- No intervention(other)
- Enrollment
- 200 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2025 – 2028
Study locations (9)
- Medical Research of Arizona, Phoenix, Arizona, United States
- John Hopkins University, Baltimore, Maryland, United States
- Washington University, St Louis, Missouri, United States
- Riverside Medical Group, Belleville, Belleville, New Jersey, United States
- HZRM Haemophilie-Zentrum Rhein Main, Frankfurt am Main, Hesse, Germany
- Medizinische Hochschule Hannover, Hanover, Lower Saxony, Germany
- Universitaetsklinikum Carl Gustav Carus TU Dresden, Leipzig, Saxony, Germany
- Universitaetsklinikum Schleswig Holstein - Campus Luebeck, Hamburg, Schleswig-Holstein, Germany
- Charité - Campus Charité Mitte, Berlin, Germany
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07001280 on ClinicalTrials.govOther trials for Hereditary angioedema
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07298447Donidalorsen Treatment in Children With Hereditary AngioedemaIonis Pharmaceuticals, Inc.
- RECRUITINGNANCT07559630Single-center Randomized Controlled Trial of Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidSJessica K. Stewart, MD
- RECRUITINGPHASE3NCT07428499Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)ADARx Pharmaceuticals, Inc.
- RECRUITINGNANCT07251933A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple CountriesTakeda
- ENROLLING BY INVITATIONPHASE3NCT07204938A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaAstria Therapeutics, Inc.
- RECRUITINGPHASE3NCT06960213STOP-HAE: A Phase 3 Study of ADX-324 in HAEADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT06842823A Study of Navenibart in Participants With Hereditary AngioedemaAstria Therapeutics, Inc.
- RECRUITINGPHASE4NCT06806657Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to GaradacimabCSL Behring